lung cancer trial fails, page-8

I'm just really worried that the failure of PI-88 in profitable indications is going to make people realise how inflated the market cap has become. PGL should now be trading much closer to cash value.

Any chance of getting to profitability now rests with their next-generation drug, but it's basically back to Phase I with nothing more than a hope and a prayer. The lung cancer failure casts grave doubt on Phase III efficacy, and the writing is on the wall. Sell.